Brian P Mckeon Form 4 IDEXX LABORATORIES / BRIAN P MCKEON ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

MCKEON BRIAN P

(Last) (First) (Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK ME 04092

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Executive VP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/04/2020		M		36,216	A	$79.54	60,916(1)	D
Common Stock	11/04/2020		S		1,400	D	$467.0142(2)	59,516	D
Common Stock	11/04/2020		S		6,338	D	$467.9662(3)	53,178	D
Common Stock	11/04/2020		S		9,617	D	$469.0944(4)	43,561	D
Common Stock	11/04/2020		S		2,850	D	$469.7968(5)	40,711	D
Common Stock	11/04/2020		S		2,493	D	$471.0224(6)	38,218	D
Common Stock	11/04/2020		S		1,107	D	$472.196(7)	37,111	D
Common Stock	11/04/2020		S		2,407	D	$473.0377(8)	34,704	D
Common Stock	11/04/2020		S		244	D	$473.9679(9)	34,460	D
Common Stock	11/04/2020		S		3,474	D	$475.2004(10)	30,986	D
Common Stock	11/04/2020		S		3,596	D	$476.0122(11)	27,390	D
Common Stock	11/04/2020		S		390	D	$477.0165(12)	27,000	D
Common Stock	11/04/2020		S		1,534	D	$479.6945(13)	25,466	D
Common Stock	11/04/2020		S		566	D	$480.3068(14)	24,900	D
Common Stock	11/04/2020		S		200	D	$481.26	24,700	D
Common Stock								28,050	I	by Estony McKeon Family, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right-to-buy)	$79.54	11/04/2020		M			36,216	(15)	02/13/2025	Common Stock	36,216	(16)	0	D

Explanation of Responses:

1. Includes 18 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2020 and excludes 28,050 shares previously owned directly which were contributed to the Estony McKeon Family, LLC on August 21, 2020.

2. Represents the weighted average price of the shares sold ranging from a low of $466.36 to a high of $467.31 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

3. Represents the weighted average price of the shares sold ranging from a low of $467.38 to a high of $468.38 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

4. Represents the weighted average price of the shares sold ranging from a low of $468.39 to a high of $469.39 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

5. Represents the weighted average price of the shares sold ranging from a low of $469.40 to a high of $470.37 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

6. Represents the weighted average price of the shares sold ranging from a low of $470.43 to a high of $471.43 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

7. Represents the weighted average price of the shares sold ranging from a low of $471.44 to a high of $472.34 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

8. Represents the weighted average price of the shares sold ranging from a low of $472.46 to a high of $473.46 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

9. Represents the weighted average price of the shares sold ranging from a low of $473.5275 to a high of $474.46 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

10. Represents the weighted average price of the shares sold ranging from a low of $474.63 to a high of $475.63 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

11. Represents the weighted average price of the shares sold ranging from a low of $475.70 to a high of $476.51 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

12. Represents the weighted average price of the shares sold ranging from a low of $476.785 to a high of $477.25 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

13. Represents the weighted average price of the shares sold ranging from a low of $479.14 to a high of $480.135 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

14. Represents the weighted average price of the shares sold ranging from a low of $480.17 to a high of $480.53 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

15. Grant of option to buy 18,108 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

16. Not applicable.

	/s/ Lily J. Lu, Attorney-in-Fact for Brian P. McKeon	11/06/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.